Notice of Intent to Award a Sole Source Contract to Biolog
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Food and Drug Administration plans to award a sole source firm-fixed price purchase order to Biolog Inc. for the Integrated Dual-Mode Microbial Phenotypic Analysis System, citing that Biolog is the exclusive manufacturer capable of providing a platform that integrates with the FDA’s existing phenotypic microarray plates and validated workflows, uniquely combining redox respiration and optical density growth kinetics measurements. The acquisition falls under FAR Part 6.302-1 due to the absence of any other supplier meeting the agency’s specific technical requirements and is being conducted under simplified acquisition procedures per FAR Part 12 as a commercial product purchase, with the NAICS code 334516 applicable to analytical laboratory instrument manufacturing. This notice does not solicit competitive bids, but any other company wishing to be considered must submit a detailed capability statement to Janice Heard at janice.heard@fda.hhs.gov no later than July 9, 2026. Responses will be evaluated solely to determine if they can meet the unique performance criteria, and the government retains full discretion to decide whether to open the requirement to competition based on any submissions received. The contract will be performed in Laurel, Maryland, with the FDA’s Rockville, Maryland office serving as the point of administrative contact.
General Info
Agency
NAICS
Place of Performance
Laurel, MD, 20708, USASet-Aside
Documents
(1)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Notice of Intent to Award a Sole Source Contract to Biolog (FDA-133991)
The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price commercial Purchase Order (PO) to Biolog Inc. 21124 Cabot Blvd., Hayward, CA 94545 for the Purchase of Integrated Dual-Mode Microbial Phenotypic Analysis System in accordance with the authority under FAR RFO Part 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The NAICS Code for this action is 334516–Analytical Laboratory Instrument Manufacturing industry. This acquisition is being conducted using simplified acquisition procedures in accordance with FAR RFO Part 12 for the acquisition of commercial products and commercial services.
Biolog is the only manufacturer of the Integrated Dual-Mode Microbial Phenotypic Analysis System that is uniquely capable of integrating with the FDA's existing maintaining compatibility with phenotypic microarray plates and validated workflows. Market research did not identify any alternative analyzers capable of providing an integrated platform that simultaneously measures redox respiration and optical density growth kinetics, compatibility with proprietary phenotypic microarray plates currently in use.
This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement to Janice Heard at janice.heard@fda.hhs.gov no later than July 09, 2026. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.